Evidence map›Paper›PMID 33230647›Full record

Trial reportInternational journal of hematology2021

Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.

Takeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa, Tsutomu Takahashi, Maki Hagihara, Hiroatsu Iida, Koichiro Minauchi, Etsuko Yamazaki, Isamu Sugiura, Tohru Murayama and 11 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. A missense mutation in themicroPublication biology · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Takeshi SaitoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. takexsaito@jikei.ac.jp.
Yoshihiro HattaDivision of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
Fumihiko HayakawaDivision of Cellular and Genetic Sciences, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tsutomu TakahashiDepartment of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.
Maki HagiharaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
Hiroatsu IidaNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Koichiro MinauchiDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Etsuko YamazakiClinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan.
Isamu SugiuraDivision of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
Tohru MurayamaDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Toru SakuraLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Naoki MoriDepartment of Hematology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Kiyotoshi ImaiDepartment of Hematology, Otaru General Hospital, Otaru, Japan.
Yuichi YahagiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Akiko Moriya SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Akihiro HirakawaDivision of Biostatics and Data Science, Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Hospital, Faculty of Medicine, Osaka, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Japan Adult Leukemia Study Group
Jikei University School of Medicine · JPGunma Saiseikai Maebashi Hospital · JPKindai University Hospital · JPNational Hospital Organization · JPNihon University · JPShimane University Hospital · JPTokyo Medical and Dental University · JPYokohama City University Hospital · JPNagasaki University · JPOtaru Municipal Hospital · JPSapporo Hokuyu Hospital · JPToyohashi Municipal Hospital · JP

Funding

Japan Agency for Medical Research and Development Grant Number JP19ck0106331
6 · The paper itself

Abstract

This phase 1/2 study aimed to identify the maximum tolerated dose, the recommended phase 2 dose (RP2D), and efficacy of the clofarabine, etoposide, and cyclophosphamide combination regimen in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients aged ≥ 15 years with relapsed/refractory ALL were enrolled. Escalating doses of clofarabine (20-30 mg/m

Indexed as

Salvage TherapyAdolescentAdultAllograftsAntineoplastic Combined Chemotherapy ProtocolsClofarabineCombined Modality TherapyCyclophosphamideDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansJapanClofarabineCyclophosphamideEtoposideAcute lymphoblastic leukemiaAdultsClofarabineCombination chemotherapyPhase 1/2

Identifiers

PMID33230647
OpenAlexW3107516579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.